SBFMW — Sunshine Biopharma Inc. Warrant
NASDAQ
$0.04
-$0.01 (-18.84%)
Sunshine Biopharma Inc. Warrant (SBFMW) common stock listed on NASDAQ. It is led by Steve N. Slilaty Ph.D., based in 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301, with about 50 employees. Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Latest reported SBFMW revenue for 2025-09-30 was $9.4M. Net income was -$883.8K. Revenue was up 0.1% from 2025-06-30 to 2025-09-30.
Use this SBFMW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SBFMW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SBFMW SEC filings page. Lician reads the product cache first so this HTML stays unique to Sunshine Biopharma Inc. Warrant even when a live quote feed is slow.
About Sunshine Biopharma Inc. Warrant
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
SBFMW Key Statistics
Market Cap
$0.00M
Volume
1,650
Previous Close
$0.05
Day Range
$0.03 – $0.24
EPS
-$7.32
Revenue
$34.87M
Net Income
-$5.13M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+44.7%
Profit Margin
-14.7%
Employees
50
SBFMW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $34.87M | $24.09M | $4.35M | $228.43K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$5.13M | -$4.51M | -$26.74M | -$12.46M |
| EPS (Diluted) | -$7.32 | -$351.36 | -$1.76 | -$4.76 |
Total Assets
$30.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$12.53M
Free Cash Flow
$0.00
Sunshine Biopharma Inc. Warrant Company Information
- Chairman, President & CEO
- Steve N. Slilaty Ph.D.
- Headquarters
- 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301
- Website
- sunshinebiopharma.com
- Phone
- 954 330 0684
- IPO / Founded
- 2022-02-15